Based on the GLOBOCAN2012, esophageal carcinoma is the eighth most common cancer worldwide, and the sixth most common cause of death from cancer; however, it is one of the least studied.([@b1]) Despite the advance in the diagnosis, staging, and treatment in recent years, the overall survival (OS) of esophageal carcinoma is still unsatisfactory.

Esophageal squamous cell carcinoma (ESCC) accounts for most esophageal malignancy in East Asia, including China,([@b2]) and southern Africa, and its incidence remains relatively constant. Esophageal adenocarcinoma (EAC), including adenocarcinoma of the esophagogastric junction, has increased rapidly in North America and Europe.([@b3]) Substantial alcohol intake as a main contributor for ESCC has been proved by a large number of well-designed epidemiological studies.([@b4]--[@b9]) According to a recent World Cancer Research Fund report,([@b10]) alcohol is considered a "convincing" risk factor for esophageal carcinoma. Alcohol causes chronic irritation and inflammation of the esophageal mucosa, and consequently induces a series of molecular changes, triggering carcinogenesis.([@b11]) Alcohol may promote the development of specific types of esophageal carcinoma, and it is possible that alcohol influences the behavior and course of the disease and has an effect on outcomes. However, the association between alcohol consumption and increased risk of EAC was not observed by etiology studies,([@b9],[@b12],[@b13]) and this reflects the different biological behavior of these two subtypes. Previous studies have proved that alcohol consumption shortened survival in patients with head and neck cancer.([@b14]--[@b16]) So far, data that elucidate the prognostic role of alcohol in patients with esophageal carcinoma have been limited; moreover, they are contradictory.([@b17]--[@b21])

Alcohol drinking is associated with many factors that potentially contribute to poorer cancer survival: male gender,([@b22],[@b23]) cigarette smoking,([@b24],[@b25]) body size,([@b26]) sporadic incidence, malnutrition, comorbidity, advanced stage at diagnosis, insufficient treatment, impaired immune function,([@b27]) and an increased molecular biological alteration that could lead to accelerated carcinogenesis and progression.([@b11]) Herein, we report the findings of a large cohort study to determine whether alcohol drinking predicts survival independently, and whether survival effects are mediated through stage disparity, cigarette smoking, and/or gender inequality.

Materials and Methods
=====================

Study population
----------------

An esophageal carcinoma database was prospectively created for cohort study sponsored by the Guangdong Esophageal Cancer Institute (Guangzhou, China). All patients, who underwent esophagectomy between January 1997 and December 2008 at Sun Yat-sen University Cancer Center (Guangzhou, China), representative of the Chinese population, were enrolled at discharge. The database includes information regarding sociodemographic data, disease extent, treatment given, and follow-up status. Excluding 18 patients with unavailable information on drinking status and/or alcohol consumption amount, and 5 patients with distant metastasis at diagnosis, 2151 patients finally constituted our study cohort. This study was approved by the Ethics Committee of the Sun Yat-sen University Cancer Center. Informed consent was obtained from all patients.

Data collection
---------------

Patients were asked to report their lifetime history of drinking and smoking, including status, frequency, average consumption amount, and type of alcohol, at the time of admission. We calculated alcohol drinks per day from patients\' responses for usual frequency and portion size of wine, spirit, and beer consumption. One drink corresponded to one serving of the US Department of Agriculture\'s food guide pyramid: one 12-fluid ounce beer, one 5-fluid ounce glass of wine, or one 1.5-ounce shot of spirit (each approximately 13 g of alcohol).([@b9]) According to the average amount of alcohol consumption per day, drinkers were classified as light drinkers (0--0.99 drinks per day), moderate drinkers (1--2.99 drinks per day), or heavy drinkers (≥3 drinks per day).([@b28])

The most common surgical approaches included left transthoracic and right transthoracic procedures (including Ivor Lewis and McKeown esophagectomy). Lymph node dissection including standard, extended, and total dissection of thoracic and abdominal lymph nodes was carried out in patients with no evidence of metastatic disease that included cervical or coeliac lymph node metastases. Tumors were staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) staging system.([@b29]) Patients were classified according to Asian-specific body mass index cut-off values([@b30]) as follows: underweight, \<18.5 kg/m^2^; normal weight, 18.5--22.9 kg/m^2^; and overweight and obese, ≥23.0 kg/m^2^.

Follow-up
---------

The patients were followed every 3 months for the first year and then every 6 months for the next 2 years, and finally annually. The diagnostic examinations consisted of esophagography, computed tomography, chest X-ray, abdominal ultrasonography, and bone scan when necessary to detect recurrence and/or metastasis. Follow-up time was calculated from the date of surgery to the date of the last contact. The primary endpoint was OS, which was calculated from the time of surgery to the time of death from any cause. The secondary endpoint was disease-free survival (DFS), which was calculated from the time from surgery to the first recurrence or metastasis of cancer, or to esophageal carcinoma-specific survival.

Statistical analysis
--------------------

All statistical analyses were carried out using [spss]{.smallcaps} 16.0 for Windows software (SPSS, Chicago, IL, USA). The distributions of demographic, epidemiological, and clinicopathologic parameters between never- and ever-drinkers, were obtained through the χ^2^-test or Fisher\'s exact test. Overall and stratified survival was estimated and plotted using the Kaplan--Meier method and log--rank test. Cox proportional hazards regression modeling was applied to calculate the crude and adjusted hazard ratios (HR) and 95% confidence intervals (CI). We tested for linear trends by modeling the median of each category as a continuous variable and testing the significance of the term in a likelihood ratio test. Statistical significance was set at 0.05, and all tests were two-sided.

Results
=======

Patient characteristics by drinking status
------------------------------------------

The population consisted of 1500 (69.7%) never-drinkers and 651 (30.3%) ever-drinkers, including former or current drinkers. As Table [1](#tbl1){ref-type="table"} shows, the majority of ever-drinkers were male (98.6%), younger (65.5%) and ever-smokers (92.8%). At the time of diagnosis, ever-drinkers were less likely to be overweight or obese, and had a higher likelihood of weight loss at the time of diagnosis. Drinking status correlated significantly with histology and stage distribution, with ever-drinkers having more ESCC and stage III disease (both *P* \< 0.001).

###### 

Clinical and pathologic characteristics of esophageal cancer patients at baseline, stratified by alcohol drinking status

  Parameter                Overall, *n* = 2151[†](#tf1-1){ref-type="table-fn"}   Never drinkers, *n* = 1500 (%)   Ever drinkers, *n* = 651 (%)   *P*-value, χ^2^-test
  ------------------------ ----------------------------------------------------- -------------------------------- ------------------------------ ----------------------
  Gender                                                                                                                                         
   Male                    1653                                                  1011 (67.4)                      642 (98.6)                     \<0.001
   Female                  498                                                   489 (32.6)                       9 (1.4)                        
  Age, years                                                                                                                                     
   ≤60                     1290                                                  864 (57.6)                       426 (65.5)                     0.001
   \>60                    861                                                   636 (42.4)                       225 (34.5)                     
  BMI, kg/m^2^                                                                                                                                   
   \<18.5                  331                                                   233 (15.6)                       98 (15.1)                      0.012
   18.5--22.9              1150                                                  772 (51.6)                       378 (58.1)                     
   ≥23                     666                                                   491 (32.8)                       175 (26.9)                     
  Weight loss                                                                                                                                    
   No                      1146                                                  838 (55.9)                       308 (47.5)                     \<0.001
   Yes                     1001                                                  660 (44.1)                       341 (52.5)                     
  Smoking status                                                                                                                                 
   Never-smokers           771                                                   724 (48.3)                       47 (7.2)                       \<0.001
   Ever-smokers            1380                                                  776 (51.7)                       604 (92.8)                     
  Histology                                                                                                                                      
   SCC                     1851                                                  1251 (83.4)                      600 (92.2)                     \<0.001
   AC                      195                                                   168 (11.2)                       27 (4.1)                       
   Other                   105                                                   81 (5.4)                         24 (3.7)                       
  AJCC stage                                                                                                                                     
   0+ I                    182                                                   140 (9.5)                        42 (6.6)                       \<0.001
   II                      951                                                   695 (47.1)                       256 (40.4)                     
   III                     978                                                   642 (43.5)                       336 (53.0)                     
  No. of comorbidities                                                                                                                           
   0                       1541                                                  1084 (72.3)                      457 (70.2)                     0.477
   ≥1                      608                                                   414 (27.6)                       194 (29.8)                     
  Surgical procedure                                                                                                                             
   Left transthoracic      1460                                                  1004 (66.9)                      456 (70.0)                     0.096
   Right transthoracic     500                                                   359 (23.9)                       141 (21.7)                     
   Others                  191                                                   137 (9.1)                        54 (8.3)                       
  Radicality of surgery                                                                                                                          
   R0                      1885                                                  1325                             560                            0.134
   R1+ R2                  146                                                   94                               52                             
  Preoperative treatment                                                                                                                         
   None                    2016                                                  1416 (94.5)                      600 (92.4)                     0.298
   Chemotherapy            49                                                    31 (2.1)                         18 (2.8)                       
   Radiotherapy            40                                                    25 (1.7)                         15 (2.3)                       
   Chemoradiotherapy       42                                                    26 (1.7)                         16 (2.5)                       
  Adjuvant treatment                                                                                                                             
   None                    1424                                                  982 (79.5)                       442 (79.9)                     0.966
   Chemotherapy            238                                                   167 (13.5)                       71 (12.8)                      
   Radiotherapy            89                                                    60 (4.9)                         29 (5.2)                       
   Chemoradiotherapy       37                                                    26 (2.1)                         11 (2.0)                       

AC, adenocarcinoma; AJCC, American Joint Committee on Cancer; BMI, body mass index; SCC, squamous cell carcinoma.

Numbers may not sum to the total because of missing data.

Survival analysis according to drinking status
----------------------------------------------

The median follow-up was 64 months with a follow-up rate of 83.9%, and the median OS and DFS was 36 months (95% CI, 32.6--39.4) and 29 months (95% CI, 25.7--32.3). The median OS for never-drinkers and ever-drinkers was 42 months (95% CI, 35.7--48.2) and 27 months (95% CI, 22.8--31.2), and median DFS was 33 months (95% CI, 28.5--37.5) and 22 months (95% CI, 18.5--25.5), respectively. The crude Kaplan--Meier survival curves in Figure [1](#fig01){ref-type="fig"}(a,b) showed worse prognosis among ever-drinkers in terms of OS and DFS (both log--rank *P* \< 0.001), and the univariate HR for ever-drinkers was 1.43 (95% CI, 1.27--1.61; *P* \< 0.001) and 1.34 (95% CI, 1.21--1.53; *P* \< 0.001) for OS and DFS, respectively.

![Kaplan--Meier survival curves are shown for overall survival (a) and disease-free survival (b) in patients with esophageal carcinoma according to alcohol drinking status. Kaplan--Meier survival curves are shown for overall survival (c) and disease-free survival (d) in patients with esophageal carcinoma according to average alcohol consumption per day. *P*-values were calculated using the unadjusted log--rank test.](cas0105-1638-f1){#fig01}

In addition, gender (*P* = 0.004), age (*P* = 0.002), weight loss (*P* = 0.002), stage (*P* \< 0.001), radicality of surgery (*P* \< 0.001), and adjuvant treatment (*P* = 0.011) were independent predictors of OS in multivariate Cox regression analysis adjusted for the baseline parameters (Table [2](#tbl2){ref-type="table"}). Ever-drinking was associated with deleterious levels of four of the six aforementioned predictors, except age and adjuvant treatment. Younger age at the time of diagnosis was the only protective association that ever-drinkers had.

###### 

Prognostic significance of baseline parameters in esophageal cancer patients by univariate and multivariate Cox regression analysis

  Parameter                No. of events/No. at risk   Univariate analysis   Multivariate analysis[†](#tf2-1){ref-type="table-fn"}                       
  ------------------------ --------------------------- --------------------- ------------------------------------------------------- ------------------- ---------
  Gender                                                                                                                                                 
   Male                    1011/642                    1.00                                                                          1.00                0.004
   Female                  250/248                     0.71 (0.61--0.81)     \<0.001                                                 0.80 (0.68--0.93)   
  Age, years                                                                                                                                             
   ≤60                     720/570                     1.00                                                                          1.00                0.002
   \>60                    541/320                     1.14 (1.02--1.28)     0.018                                                   1.86 (1.07--1.33)   
  BMI, kg/m^2^                                                                                                                                           
   \<18.5                  228/103                     1.18 (1.01--1.37)     0.034                                                   --                  --
   18.5--22.9              669/481                     1.00                                                                          --                  
   ≥23                     358/308                     0.86 (0.76--0.98)     0.021                                                   --                  
  Weight loss                                                                                                                                            
   No                      622/524                     1.00                                                                          1.00                0.002
   Yes                     639/362                     1.31 (1.17--11.46)    \<0.001                                                 1.21 (1.07--1.37)   
  Smoking status                                                                                                                                         
   Never--smokers          403/368                     1.00                                                                          --                  
   Ever--smokers           858/522                     1.36 (1.20--1.53)     \<0.001                                                 --                  
  Histology                                                                  0.033                                                                       
   SCC                     1087/764                    1.00                                                                          --                  --
   AC                      131/64                      1.25 (1.04--1.51)     0.018                                                   --                  
   Other                   63/42                       1.20 (0.92--1.56)     0.182                                                   --                  
  AJCC stage                                                                 \<0.001                                                                     
   0+ I                    50/132                      1.00                                                                          1.00                \<0.001
   II                      494/457                     2.07 (1.55--2.76)     \<0.001                                                 2.09 (1.52--2.86)   
   III                     716/262                     4.71 (3.54--6.26)     \<0.001                                                 4.44 (3.24--6.08)   
  No. of comorbidities                                                                                                                                   
   0                       909/634                     1.00                                                                          --                  
   ≥1                      352/256                     1.02 (0.90--1.150)    0.775                                                   --                  
  Surgical procedure                                                                                                                                     
   Left transthoracic      883/577                     1.00                                                                          --                  --
   Right transthoracic     266/234                     0.87 (0.76--0.99)     0.040                                                   --                  
   Others                  112/79                      0.96 (0.79--1.18)     0.717                                                   --                  
  Radicality of surgery                                                                                                                                  
   R0                      1075/810                                                                                                  1.00                \<0.001
   R1+ R2                  125/21                      2.91 (2.43--3.48)     \<0.001                                                 2.29 (1.84--2.86)   
  Preoperative treatment                                                                                                                                 
   None                    1185/831                    1.00                                                                          --                  --
   Chemotherapy            30/21                       1.53 (1.05--2.24)     0.029                                                   --                  
   Radiotherapy            25/16                       1.26 (0.84--1.88)     0.266                                                   --                  
   Chemoradiotherapy       21/22                       0.95 (0.61--1.47)     0.81                                                    --                  
  Adjuvant treatment                                                                                                                                     
   None                    847/573                     1.00                                                                          1.00                0.011
   Chemotherapy            124/115                     0.97 (0.80--1.17)     0.757                                                   0.71 (0.58--0.87)   
   Radiotherapy            73/16                       1.83 (1.44--2.32)     \<0.001                                                 0.96 (0.73--1.25)   
   Chemoradiotherapy       29/10                       1.54 (1.05--2.24)     0.026                                                   0.86 (0.57--1.28)   

AC, adenocarcinoma; AJCC, American Joint Committee on Cancer; BMI, body mass index; CI, confidence interval; HR, hazard ratio; SCC, squamous cell carcinoma.

Multivariate analysis included all these baseline parameters. --, not included in the multivariate analysis.

To determine whether the crude hazard association between drinking status and OS was mediated by other important prognostic factors, Cox proportional hazard models were used, adjusted for baseline covariates (model A), additionally adjusted for smoking status (model B), and then additionally adjusted for gender (model C). In the Cox model that was adjusted for the baseline covariates, which includes age, weight loss prior to diagnosis, AJCC stage, radicality of surgery, and adjuvant treatment, the HR for ever-drinkers was 1.30 (95% CI, 1.14--1.47; *P* \< 0.001) (Table [3](#tbl3){ref-type="table"}, model A). The multivariate HR for ever-drinkers declined by 30.2% (1.43 *vs* 1.30) following adjustment for baseline covariates. Additionally adjusted for smoking status, the HR for ever-drinkers was 1.24 (95% CI, 1.08--1.43; *P* = 0.002) (Table [3](#tbl3){ref-type="table"}, model B). Adjusted for baseline covariates, smoking status, and gender, the prognostic effect of drinking remained significant, and the HR was 1.22 (95% CI, 1.06--1.41; *P* = 0.005) (Table [3](#tbl3){ref-type="table"}, model C). Ever-drinking was also shown to be an independent prognostic factor of DFS (Table [3](#tbl3){ref-type="table"}).

###### 

Three multivariate Cox models for alcohol drinking status on overall survival and disease--free survival among patients with esophageal carcinoma

                                             Model A adjusted for baseline covariates[†](#tf3-1){ref-type="table-fn"}   Model B adjusted for baseline covariates[†](#tf3-1){ref-type="table-fn"} and smoking   Model C adjusted for baseline covariates,[†](#tf3-1){ref-type="table-fn"}smoking, and gender
  ------------------------------------------ -------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Overall survival                                                                                                                                                                                             
   Drinking status (ever *vs* never)         1.30 (1.14--1.47, *P* \< 0.001)                                            1.24 (1.08--1.43, *P* = 0.002)                                                         1.22 (1.06--1.41, *P* = 0.005)
   Age, years (\>60 *vs* ≤60)                1.22 (1.08--1.38,*P* = 0.002)                                              1.22 (1.08--1.39, *P* = 0.001)                                                         1.23 (1.08--1.39, *P* = 0.001)
   Weight loss (yes *vs* no)                 1.18 (1.04--1.33, *P* = 0.009)                                             1.18 (1.04--1.33, *P* = 0.009)                                                         1.18 (1.05--1.34, *P* = 0.007)
  AJCC stage                                                                                                                                                                                                   
   0+ I                                      1.00                                                                       1.00                                                                                   1.00
   II                                        2.08 (1.52--2.85, *P* \< 0.001)                                            2.08 (1.52--2.85, *P* \< 0.001)                                                        2.09 (1.53--2.86, *P* \< 0.001)
   III                                       4.49 (3.28--6.14, *P* \< 0.001)                                            4.46 (3.26--6.10, *P* \< 0.001)                                                        4.46 (3.26--6.11, *P* \< 0.001)
   Radicality of surgery (R1 + R2 *vs* R0)   2.14 (1.72--2.66, *P* \< 0.001)                                            2.16 (1.74--2.68, *P* \< 0.001)                                                        2.17 (1.75--2.70, *P* \< 0.001)
  Adjuvant treatment                                                                                                                                                                                           
   None                                      1.00                                                                       1.00                                                                                   1.00
   Chemotherapy                              0.71 (0.59--0.87, *P* = 0.001)                                             0.72 (0.59--0.87, *P* = 0.001)                                                         0.71 (0.58--0.86, *P* = 0.708)
   Radiotherapy                              1.04 (0.80--1.35, *P* = 0.792)                                             1.03 (0.79,1.34, *P* = 0.812)                                                          1.02 (0.78--1.32, *P* = 0.907)
   Chemoradiotherapy                         0.88 (0.60--1.30, *P* = 0.521)                                             0.89 (0.60--1.31, *P* = 0.131)                                                         0.88 (0.60--1.30, *P* = 0.525)
   Smoking status (ever *vs* never)                                                                                     1.12 (0.97--1.29, *P* = 0.131)                                                         1.02 (0.85--1.22, *P* = 0.836)
   Gender (female *vs* male)                                                                                                                                                                                   0.85 (0.69--1.05, *P* = 0.124)
  Disease-free survival                                                                                                                                                                                        
   Drinking status (ever *vs* never)         1.22 (1.07--1.39, *P* = 0.002)                                             1.17 (1.012--1.35, *P* = 0.027)                                                        1.16 (1.01--1.34, *P* = 0.037)
   Age, years (\>60 *vs* ≤60)                1.19 (1.05--1.34, *P* = 0.006)                                             1.19 (1.05--1.34, *P* = 0.006)                                                         1.19 (1.05--1.34, *P* = 0.004)
   Weight loss (yes *vs* no)                 1.12 (0.99--1.26, *P* = 0.073)                                             1.12 (0.99--1.26, *P* = 0.072)                                                         1.12 (0.99--1.27, *P* = 0.067)
  AJCC stage                                                                                                                                                                                                   
   0+ I                                      1.00                                                                       1.00                                                                                   1.00
   II                                        2.21 (1.62--3.00, *P* \< 0.001)                                            2.21 (1.63--3.01, *P* \< 0.001)                                                        2.22 (1.63--3.01, *P* \< 0.001)
   III                                       4.75 (3.49--6.46, *P* \< 0.001)                                            4.72 (3.47--6.43, *P* \< 0.001)                                                        4.73 (3.47--6.43, *P* \< 0.001)
   Radicality of surgery (R1+ R2 *vs* R0)    1.78 (1.43--2.22, *P* \< 0.001)                                            1.78 (1.43--2.22, *P* \< 0.001)                                                        1.79 (1.44--2.24, *P* \< 0.001)
  Adjuvant treatment                                                                                                                                                                                           
   None                                      1.00                                                                       1.00                                                                                   1.00
   Chemotherapy                              0.83 (0.68--1.01, *P* = 0.056)                                             0.83 (0.69--1.01, *P* = 0.062)                                                         0.83 (0.68--1.00, *P* = 0.055)
   Radiotherapy                              1.12 (0.86--1.45, *P* = 0.409)                                             1.11 (0.86--1.45, *P* = 0.426)                                                         1.10 (0.85--1.44, *P* = 0.466)
   Chemoradiotherapy                         0.87 (0.59--1.30, *P* = 0.508)                                             0.89 (0.0--1.32, *P* = 0.548)                                                          0.88 (0.59--1.31, *P* = 0.533)
   Smoking status (ever *vs* never)                                                                                     1.11 (0.97--1.28, *P* = 0.144)                                                         1.06 (0.88--1.27, *P* = 0.563)
   Gender (female *vs* male)                                                                                                                                                                                   0.91 (0.74--1.12, *P* = 0.392)

AJCC, American Joint Committee on Cancer.

Baseline covariates include age, weight loss, stage, radicality of surgery, and adjuvant treatment.

Survival analysis according to the average amount of alcohol consumption
------------------------------------------------------------------------

According to the average amount of alcohol consumption per day, patients were classified as never drinkers (*n* = 1500, 69.7%), light drinkers (*n* = 139, 6.5%), moderate drinkers (*n* = 309, 14.4%), or heavy drinkers (*n* = 202, 9.4%). The crude OS and DFS curves by these four categories are shown in Figure [1](#fig01){ref-type="fig"}(c,d). Compared to never-drinkers, the univariate HRs for light, moderate, and heavy drinkers were 1.19 (95% CI, 0.94--1.51; *P* = 0.147), 1.36 (95% CI, 1.17--1.58; *P* \< 0.001) and 1.76 (95% CI, 1.47--2.10; *P* \< 0.001) in terms of OS. These univariate HRs were 1.14 (95% CI, 0.89--1.44; *P* = 0.298), 1.33 (95% CI, 1.14--1.54; *P* \< 0.001), and 1.61 (95% CI, 1.34--1.93; *P* \< 0.001) in terms of DFS. The hazardous effect of drinking on OS and DFS increased markedly across alcohol consumption categories (both *P*-value for trend \<0.001), indicating the dose--response relationship between alcohol consumption and survival. Instead of drinking status, the category of alcohol consumption amount was included in the three multivariate Cox models successively (Table [4](#tbl4){ref-type="table"}). The independent effect of heavy drinking remained in all three models. We observed an association between moderate drinking and poor OS in both model A and B, however, this association become marginally significant (*P* = 0.057), adjusted for baseline covariates, smoking status, and gender. The dose--response relationship remained statistically significant in all three models.

###### 

Univariate analysis and three multivariate Cox models for alcohol consumption amount per day on overall survival and disease-free survival among patients with esophageal carcinoma

  Average alcohol consumption                            Crude HR (95% CI, *P*-value)      Model A, adjusted for baseline covariates[†](#tf4-1){ref-type="table-fn"}   Model B, adjusted for baseline covariates[†](#tf4-1){ref-type="table-fn"} and smoking   Model C, adjusted for baseline covariates,[†](#tf4-1){ref-type="table-fn"} smoking, and gender
  ------------------------------------------------------ --------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Overall survival                                                                                                                                                                                                                                             
   Never (*n* = 1500)                                    1.00                              1.00                                                                        1.00                                                                                    1.00
   Light (*n* = 139)                                     1.19 (0.94--1.51, *P* = 0.147)    1.04 (0.80--1.37, *P* = 0.751)                                              1.00 (0.76--1.31, *P* = 0.993)                                                          0.99 (0.75--1.30, *P* = 0.928)
   Moderate (*n* = 309)                                  1.36 (1.17--1.58, *P* \< 0.001)   1.25 (1.06--1.48, *P* = 0.008)                                              1.20 (1.01--1.4328, *P* = 0.041)                                                        1.19 (1.00--1.41, *P* = 0.057)
   Heavy (*n* = 202)                                     1.76 (1.47--2.10, *P* \< 0.001)   1.55 (1.27--1.88, *P* \< 0.001)                                             1.48 (1.21--1.82, *P* \< 0.001)                                                         1.46 (1.19--1.79, *P* \< 0.001)
   P value for trend^2^                                  0.005                             0.004                                                                       0.013                                                                                   0.016
  Disease-free survival                                                                                                                                                                                                                                        
   Never (*n* = 1500)                                    1.00                              1.00                                                                        1.00                                                                                    1.00
   Light (*n* = 139)                                     1.14 (0.89--1.44, *P* = 0.298)    1.02 (0.78--1.33, *P* = 0.907)                                              0.97 (0.74--1.28, *P* = 0.849)                                                          0.97 (0.74--1.20, *P* = 0.811)
   Moderate (*n* = 309)                                  1.33 (1.14--1.54, *P* \< 0.001)   1.20 (1.02--1.42, *P* = 0.027)                                              1.15 (0.97--1.37, *P* = 0.108)                                                          1.14 (0.96--1.36, *P* = 0.127)
   Heavy (*n* = 202)                                     1.61 (1.34--1.93, *P* \< 0.001)   1.43 (1.17--1.75, *P* \< 0.001)                                             1.37 (1.12--1.88, *P* = 0.003)                                                          1.36 (1.11--1.67, *P* = 0.004)
   *P*-value for trend[‡](#tf4-2){ref-type="table-fn"}   0.002                             0.009                                                                       0.025                                                                                   0.026

Baseline covariates include age, weight loss, stage, radicality of surgery, and adjuvant treatment.

*P*-value for trend was calculated by modeling the median of each categories as a continuous variable.

Subgroup analysis
-----------------

Overall survival analyses stratified by covariates were carried out using the Kaplan--Meier method. Compared with never-drinkers, the survival of ever-drinkers was significantly shorter in males, younger patients, all three body mass index categories, both weight-loss subgroups, both never- and ever-smokers, patients with ESCC, stage II and III diseases, patients with or without pretreatment comorbidities, and the R0 subgroup ([Table S1](#SD1){ref-type="supplementary-material"}).

In patients with ESCC, ever-drinkers had significantly poorer OS (median, 49 months *vs* 28 months, *P* \< 0.001) (Fig. [2](#fig02){ref-type="fig"}a) and DFS (median, 36 months *vs* 22 months, *P* \< 0.001) (Fig. [2](#fig02){ref-type="fig"}b). Among patients with EAC, including adenocarcinoma of the esophagogastric junction, there was no significant difference between never- and ever-drinkers in OS (median, 31 months *vs* 25 months, *P* = 0.660) (Fig. [2](#fig02){ref-type="fig"}c) or DFS (median, 23 months *vs* 17 months, *P* = 0.729) (Fig. [2](#fig02){ref-type="fig"}d). In model C, adjusted for baseline covariates, smoking status, and gender, drinking status was found to be an independent prognostic factor for poorer OS (HR, 1.19; 95% CI, 1.03--1.38; *P* = 0.022) and DFS (HR, 1.18; 95% CI, 1.02--1.36; *P* = 0.023) in patients with ESCC. Among patients with EAC, drinking status was not a significant prognostic factor for OS (HR, 1.27; *P* = 0.596) or DFS (HR, 1.77; *P* = 0.207) ([Table S2](#SD2){ref-type="supplementary-material"}). In addition, the dose--response relationship also existed in the ESCC subgroup ([Table S3](#SD3){ref-type="supplementary-material"}).

![Kaplan--Meier survival curves are shown for overall survival (a) and disease-free survival (b) in patients with esophageal squamous cell carcinoma according to alcohol drinking status. Kaplan--Meier survival curves are shown for overall survival (c) and disease-free survival (d) in patients with esophageal adenocarcinoma according to alcohol drinking status. *P*-values were calculated using the unadjusted log--rank test.](cas0105-1638-f2){#fig02}

Discussion
==========

Our large-scale population study of patients with esophageal cancer revealed that prediagnosis drinking increased the hazard of dying by over 20% compared to never-drinkers. Adjusted for other important prognostic factors, the adverse association between drinking and survival remained statistically significant. Moreover, the hazardous effects of drinking grew statistically significantly in a dose-dependent manner with increasing amount of alcohol consumption per day, which was not described by previous studies.

In recent years, growing attention in cancer research has been paid to the impacts of host-related factors, including lifestyle. Goodwin([@b31]) asserted that host-related factors have characteristics that are associated with certain prognoses, so that they appear to influence prognosis. Furthermore, caution should be exercised in attributing prognostic effects to sociodemographic factors that cause delay in diagnosis and advanced tumor stage. Indeed, drinking status is associated with other prognostic factors in our study, as mentioned above. Although the injurious effects on survival attenuate after adjustment for age, weight loss at diagnosis, tumor stage, radicality of surgery, smoking status, and gender, alcohol drinking remains an important and independent predictor of unfavorable outcome. The dose--response relationship further confirms the effects.

There was no significant difference in preoperative comorbidity between never- and ever-drinkers, and comorbidity had no influence on prognosis. This might result from the fact that patients receiving surgical treatment constituted our study cohort. Patients with severe and alcohol-abuse related comorbidities were more likely to have poor cardiac, pulmonary and hepatic function, and therefore to be excluded during critical preoperative evaluation. The fact that the prevalence of comorbidity in our cohort was markedly lower than others([@b32],[@b33]) including non-surgical treatments, supported this contention. Anyway, this revealed that the prognostic effect of alcohol was not mediated through comorbidity. Alcohol drinking is thought to correlate with lower socioeconomic status (SES), which reduces the possibility of receiving reasonable multimodality treatment. In our study, treatment modality was similar between the two groups, suggesting that it was unlikely to introduce bias. Insufficient treatment shouldn\'t be the explanation of poor survival in ever-drinkers.

In the subgroup analysis, the hazardous effect of drinking existed broadly in most subgroups, but the subgroup with adenocarcinoma was an exception. The small sample size of drinkers with adenocarcinoma (*n* = 27) might restrict the power to distinguish the difference. This could be an explanation; however, this is not necessarily the case. In studies by Sundelof *et al*.,([@b18]) Trivers *et al*.,([@b19]) and Thrift *et al*.,([@b34]) alcohol drinking did not predict the survival of EAC patients, either. It seems plausible to conclude that alcohol is not a risk factor for both incidence and mortality of patients EAC. However, further validation is needed to draw the final conclusion.

There are several strengths and limitations of our study that should be considered in interpreting the results. To our knowledge, the current study has been the largest, to date, in elucidating the prognostic role of alcohol drinking in esophageal cancer. The clinicopathologic data were retrieved from medical records, and the follow-up continued over a long period of time. Patients who had an esophageal resection constitute our cohort, reducing the heterogeneity of subjects and avoiding some potential confounding factors deriving from definitive chemoradiotherapy or other therapies. In addition, this is the first to report dose-relationship between the amount of alcohol consumption and poor survival, further confirming the adverse prognostic effects of alcohol drinking.

One limitation is that our study does not evaluate behavioral change in drinking after diagnosis, which may have ongoing effects on survival. It is an important component of patient education to give strong advice on abstinence from admission to postoperative follow-up. The majority of patients would possibly comply with this advice postoperatively for fear of destroying the esophagus replacement and aggravating complications. In addition, the HRs for former- and current-drinkers were pooled during analysis. We failed to analyze the effects of former-drinkers alone and elucidate whether giving up drinking could reduce the risk of mortality.

If further investigations prove the current study results to be accurate, these finding have significant public health, clinical, and research implications. Reducing alcohol consumption is an important and underemphasized cancer prevention strategy, yet it receives little attention, especially when compared with efforts related to other cancer prevention topics such as screening, tobacco, and obesity. Given the dose--response relationship between alcohol intake and risk of mortality in esophageal carcinoma, control of heavy drinking remains the main target not only for cancer control, but also mortality reduction, at least in ESCC. Clinical investigations and trials in esophageal carcinoma should obtain detailed data on drinking status, consider drinking as a potential confounding factor of survival, and adjust for it in analysis, or stratify by drinking status. More intensive treatment and/or surveillance may be needed in patients with esophageal carcinoma who are alcohol drinkers.

Molecular biological research has revealed that alcohol and its metabolites trigger many genetic and epigenetic alterations,([@b35],[@b36]) leading to more aggressive biological behavior, cancer progression, and alcohol-associated reduced immune surveillance. For instance, alcohol consumption coupled with genetic variants in *ADH1B* and *ALDH2*, two alcohol metabolizing genes, has effects on early ESCC diagnosis and tumor dissemination.([@b36]) It is urgent to develop a better understanding of the underlying mechanisms to provide insight into esophageal carcinogenesis and uncover novel therapeutic approaches.

In summary, we carried out a large-scale investigation with long-term follow-up to evaluate the effects of prediagnosis drinking on survival in esophageal carcinoma. We observed that alcohol drinking was associated with decreased survival in ESCC, which appears not to be attributable to differences in stage, smoking status, gender, comorbidity, or treatment. The hazardous effects of alcohol grew significantly with increased alcohol consumption. Nevertheless, alcohol consumption might not be a prognostic factor in patients with EAC. The findings presented here warrant confirmation in further studies, with an emphasis on elucidating mechanisms.
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